Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Pivot

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]M P Goetz, M Toi, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINEE P Mamounas, M Untch, M S Mano, et al.
ESMO Open|May 13, 2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in FranceJ Y Blay, S Boucher, B Le Vu, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]M P Goetz, M Toi, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINEE P Mamounas, M Untch, M S Mano, et al.
ESMO Open|May 13, 2021
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in FranceJ Y Blay, S Boucher, B Le Vu, et al.
Pageof 10